New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 5 #2/3 June/July 1999
State-of-the-Art in the Management of Cancer

LUNG CANCER-PART I
ETIOLOGY AND GLOBAL EPIDEMIOLOGY

Global Epidemiology

Triad Epidemiology

Lung Cancer in the USA

Lung Cancer in Europe

Lung Cancer in Japan

Etiology

Tobacco Smoking

Environmental Factors

Hereditary Factors

Special Review

ONCOLOGY TRENDS
PRODUCT MARKETS-PART I

Platinum-based Anticancer Agents

Cisplatin

Carboplatin

Oxaliplatin

Topoisomerase I Inhibitors

Topotecan

Irinotecan

Thymidylate Synthase Inhibitors/Antifolates and Related Agents

Capecitabine

Raltitrexed

UFT

Meeting Coverage

CHEMOTHERAPY IN NON-SMALL CELL LUNG CANCER (NSCLC)

From the 35th Annual Meeting of the American Society of Clinical Oncology

Atlanta, GA; May 15-18, 1999

Approaches to Maximize the Role of Chemotherapy in NSCLC

Postoperative Adjunct Chemotherapy in Resected Disease

Neoadjuvant Chemotherapy in Resectable Disease

Neoadjuvant Chemoradiotherapy in Resectable Disease

Induction Chemotherapy and Concomitant Chemoradiotherapy in Unresectable Stage III Disease

Concurrent Versus Sequential Chemoradiotherapy in Unresectable Disease

Postoperative Chemotherapy with or without Radiotherapy in Resected Disease

Commercially Available Chemotherapeutics in Clinical Trials in Advanced Disease

Two-drug Combination/Multimodality Therapies

  • Platinum-based chemotherapy regimens
  • Taxane-based combinations
  • Other combinations

Monochemotherapies

  • Docetaxel
  • Paclitaxel
  • Vinorelbine
  • Irinotecan

Multidrug Regimens in Advanced Disease

  • Three-drug platinum-containing regimens
  • A dose-intensive 4-drug combination

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887

hublot replica
fake rolex
fake hublot